Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AT-101 + Bicalutamide |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AT-101 | R-(-)-gossypol acetic acid|AT101 | BCL2 Family Inhibitor 6 | AT-101 is a pan-BCL2 inhibitor that inhibits the anti-apoptotic proteins BCL2, BCL-XL, and MCL1, potentially resulting in increased tumor cell apoptosis and decreased cell proliferation (PMID: 26089640, PMID: 16611409, PMID: 31388792). | |
Bicalutamide | Casodex | Hormone - Anti-androgens 54 | Casodex (bicalutamide) is an androgen-receptor antagonist that binds androgen receptors and inhibits androgen binding, therefore inhibits AR-dependent growth of tumor cells (PMID: 9428389). Casodex (bicalutamide) is approved, in combination with a luteinizing hormone-releasing hormone (LHRH) analog, for metastatic carcinoma of the prostate (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|